EXTRANEAL

This brand name is authorized in United States. It is also authorized in Austria, Brazil, Croatia, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Japan, Lithuania, Malta, New Zealand, Romania, Singapore, South Africa, Spain, Tunisia, Turkey.

Active ingredients

The drug EXTRANEAL contains a combination of these active pharmaceutical ingredients (APIs):

1	Icodextrin UNII 2NX48Z0A9G - ICODEXTRIN
2	Sodium chloride UNII 451W47IQ8X - SODIUM CHLORIDE
	Sodium chloride is the principle salt involved in maintaining the osmotic tension of blood and tissues. Changes in osmotic tension influence the movement of fluids and diffusion of salts in cellular tissue.
	Read more about Sodium chloride
3	Lactic acid UNII TU7HW0W0QT - SODIUM LACTATE
	Read more about Lactic acid
4	Calcium chloride UNII M4I0D6VV5M - CALCIUM CHLORIDE
	Calcium is the most abundant mineral in the body, and is an essential body electrolyte. Homeostasis is mainly regulated by the parathyroid hormone, by calcitonin, and by the activated form of vitamin D. Calcium is a structural component of bones and teeth. It is also required for blood clotting, neurotransmitter release, muscle contraction and normal heartbeat.
	Read more about Calcium chloride
5	Magnesium chloride UNII 02F3473H9O - MAGNESIUM CHLORIDE
	Read more about Magnesium chloride

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
EXTRANEAL Solution for peritoneal dialysis	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
B05DA	Isotonic solutions	B Blood and blood forming organs → B05 Blood substitutes and perfusion solutions → B05D Peritoneal dialytics
Discover more medicines within B05DA

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	503206301134312, 503206302173419
EE	Ravimiamet	1010170, 1067666, 1067677, 1669002, 1669013, 1669024, 1669035, 1669046, 1669057, 1669068, 1669079, 1669080, 1669091, 1734173, 1734184, 1734195, 1734207, 1734229, 1734230, 1734241, 1734252, 1734263, 1734274, 1734285, 1734296, 1734308, 1734319, 1734320, 1734331, 1734342, 1734353, 1734454, 1734465, 1734476, 1734487, 1734498, 1734500, 1734511, 1734522, 1734533, 1734544, 1734735, 1734746
ES	Centro de información online de medicamentos de la AEMPS	61860
FI	Lääkealan turvallisuus- ja kehittämiskeskus	086264, 086280, 147330
FR	Base de données publique des médicaments	66121209
HK	Department of Health Drug Office	46627
HR	Agencija za lijekove i medicinske proizvode	HR-H-928997385
IL	מִשְׂרַד הַבְּרִיאוּת	9136
JP	医薬品医療機器総合機構	3420432A1038, 3420432A2034, 3420432A3030, 3420432A4037
LT	Valstybinė vaistų kontrolės tarnyba	1006817, 1015279, 1015280, 1062003, 1062004, 1062005, 1062006, 1076660, 1076661, 1076662
MT	Medicines Authority	MA1277/01101
NZ	Medicines and Medical Devices Safety Authority	9679
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W67135001, W67135002, W67135003, W67135004, W67135005, W67135006, W67135007, W67135008, W67135009, W67135010, W67135011, W67135012, W67135013, W67135014, W67135015, W67135016, W67135017, W67135018, W67135019, W67135020, W67135021, W67135022, W67135023, W67135024, W67135025, W67135026, W67135027, W67135028, W67135029, W67135030, W67135031
SG	Health Sciences Authority	11220P
TN	Direction de la Pharmacie et du Médicament	10193011, 10193012
TR	İlaç ve Tıbbi Cihaz Kurumu	8681413880605, 8681413880612, 8681413880629, 8681413880636
US	FDA, National Drug Code	0941-0679
ZA	Health Products Regulatory Authority	38/34/0172